文献速递心血管胸部CT

使用「对比剂增强优化器」减少冠状动脉CT血管成像动脉强化的个体差异:一项前瞻性随机单中心研究

Minimizing individual variations in arterial enhancement on coronary CT angiographs using "contrast enhancement optimizer": a prospective randomized single-center study.
PubMed 文献 · Eur Radiol · 2018-11-12

该单中心前瞻性随机研究将295例接受冠状动脉CT血管成像的患者随机分为两组,A组(150例)由新开发的对比剂增强优化器(CEO)根据患者因素选择碘剂量,B组(145例)采用标准方案(245 mg I/kg)。A组碘剂量显著低于B组(235.7 vs. 253.6 mg I/kg,p < 0.001),升主动脉CT值两组等效(428.6 ± 55.5 HU vs. 436.1 ± 68.7 HU,差值95%CI -4.3至16.9 HU,在预设等效界值75 HU内),A组方差显著更小(p = 0.009),CT值可接受患者比例显著更高(84.7% vs. 71.7%,p = 0.007)。

要点

  • CEO软件根据患者因素个体化选择碘剂量,使升主动脉CT值可接受的患者比例从标准方案的71.7%提高至84.7%(p = 0.007)。
  • CEO组升主动脉CT值方差显著小于标准方案组(p = 0.009),提示强化稳定性更好。
  • CEO组碘剂量显著低于标准方案组(235.7 vs. 253.6 mg I/kg,p < 0.001),且升主动脉CT值两组等效。

核心结论

  • 对于冠状动脉CT血管成像,使用CEO软件较基于体重的标准方案可使显著更多患者获得最佳升主动脉对比剂强化。

研究设计与样本

  • 前瞻性随机单中心研究,纳入295例接受冠状动脉CT血管成像的患者(男168例、女127例,中位年龄71岁),随机分为A组(n = 150,CEO根据患者因素选择碘剂量)和B组(n = 145,标准方案245 mg I/kg);以升主动脉CT值为主要指标,预设等效界值75 HU,采用F检验比较CT值标准差、卡方检验比较CT值可接受患者比例。

诊断标准与关键数值

  • 升主动脉CT值A组428.6 ± 55.5 HU vs. B组436.1 ± 68.7 HU,差值95%CI -4.3至16.9 HU,在预设等效界值75 HU内;CT值可接受患者比例A组84.7% vs. B组71.7%(p = 0.007);碘剂量A组235.7 mg I/kg vs. B组253.6 mg I/kg(p < 0.001);CT值方差A组显著小于B组(p = 0.009)。

临床应用与阅片要点

  • 作者结论认为,CEO软件用于冠状动脉CT血管成像研究时,可使显著更多患者获得最佳升主动脉对比剂强化;原文要点指出,使用CEO软件可在冠状动脉CT血管成像扫描中获得最佳且稳定的主动脉强化,不受患者因素影响,使对比剂管理更合适,并可在不同管电压水平控制对比剂强化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the clinical utility of our newly developed contrast enhancement optimizer (CEO) software for coronary CT angiography (CCTA).

METHODS: We randomly assigned 295 patients (168 males, 127 females, median age 71 years) undergoing CCTA to one of two contrast media injection protocols. Group A (n = 150) was injected with a CEO-selected iodine dose based on patient factors. In group B (n = 145), we used our standard protocol (245 mg I/kg). We recorded the CT number in the ascending aorta and determined whether the CT number was equivalent in groups A and B. For the equivalence test, we adopted 75 Hounsfield units (HU) as the equivalence margin. The standard deviation in the CT number and the rate of patients with an acceptable CT number were compared using the F test and the chi-square test, respectively.

RESULTS: The iodine dose in group A was significantly smaller than that in group B (235.7 vs. 253.6 mg I/kg, p < 0.001). The CT number of the ascending aorta was 428.6 ± 55.5 HU in group A and 436.1 ± 68.7 HU in group B; the 95% confidence interval for the difference between the groups was -4.3 HU to 16.9 HU and within the range of the predetermined equivalence margins. In group A, the variance was significantly smaller than that in group B (p = 0.009). The number of patients with an acceptable CT number was significantly higher in group A than in group B (84.7% vs. 71.7%, p = 0.007).

CONCLUSIONS: The use of our CEO for CCTA studies yielded optimal aortic contrast enhancement in significantly more patients than the standard protocol based on the body weight.

KEY POINTS: • With our contrast enhancement optimizer (CEO) software, optimal and stable aortic enhancement can be obtained on coronary CT angiography scans irrespective of patient factors. • Management of contrast media becomes more appropriate by the CEO software. • The CEO software can control contrast enhancement at different tube voltage levels.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Matsumoto Y, Higaki T, Masuda T, et al. Minimizing individual variations in arterial enhancement on coronary CT angiographs using "contrast enhancement optimizer": a prospective randomized single-center study. Eur Radiol. 2018. PMID: 30421021. doi:10.1007/s00330-018-5823-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。